| 小细胞肺癌免疫治疗相关生物标志物研究进展 |
| |
| 引用本文： | 谢梦青,储香玲,周 娟,苏春霞. 小细胞肺癌免疫治疗相关生物标志物研究进展[J]. 中国癌症杂志, 2021, 31(7): 635-639. DOI: 10.19401/j.cnki.1007-3639.2021.07.010 |
| |
| 作者姓名： | 谢梦青 储香玲 周 娟 苏春霞 |
| |
| 作者单位： | 同济大学附属上海市肺科医院肿瘤科，上海 200433 |
| |
| 基金项目： | 国家自然科学基金面上项目（81874036，82072568）；上海市科学技术委员会（19411971100）；上海市肺科医院面上项目（FKLY20013）。 |
| |
| 摘 要： | 最近30年来小细胞肺癌(small cell lung cancer,SCLC)的治疗手段无明显突破,整体预后也无显著改善.随着免疫治疗时代的开启,免疫检查点抑制剂在SCLC治疗中取得了重大进展,但整体获益仍有限.如何筛选获益人群以进一步提高免疫治疗效果是当下SCLC研究的热点问题之一.通过概述SCLC现状,聚焦SCL...
|
| 关 键 词： | 小细胞肺癌 免疫治疗 生物标志物 |
The advances in immunotherapy biomarkers of small cell lung cancer |
| |
| XIE Mengqing,CHU Xiangling,ZHOU Juan,SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer[J]. China Oncology, 2021, 31(7): 635-639. DOI: 10.19401/j.cnki.1007-3639.2021.07.010 |
| |
| Authors: | XIE Mengqing CHU Xiangling ZHOU Juan SU Chunxia |
| |
| Affiliation: | Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China; |
| |
| Abstract: | There is no obvious breakthrough in treatment for small cell lung cancer (SCLC) in more than 30 years, and the prognosis has not improved significantly. With the opening of the immune era, immune checkpoint inhibitors have made breakthroughs in SCLC treatment, but the overall benefit population is limited. How to select patients accurately and how to increase the efficacy of immunotherapy are hot topics in SCLC research. Therefore, this article summarized the current status of SCLC with focus on biomarkers related to SCLC immunotherapy, reviewed the progress in the research of immunotherapy markers in recent years, to provide clues and ideas for future immunotherapeutic strategies. |
| |
| Keywords: | Small cell lung cancer Immunotherapy Biomarkers |
|
| 点击此处可从《中国癌症杂志》浏览原始摘要信息 |
|
点击此处可从《中国癌症杂志》下载全文 |
|
